ReproNovo raises €58.5M Series A round
21 May 2025· Lausanne, Switzerland· health, reproductive_medicine, biotech, drug_development, b2b
The funding will be used to advance ReproNovo's pipeline of multiple Phase 2 programs, addressing critical gaps in reproductive medicine and women's health, including male and female infertility and uterine health. Specifically, it will fund Phase 2 clinical trials for RPN-001 (leflutrozole) for male infertility and RPN-002 (nolasiban) for adenomyosis and improving embryo implantation in assisted reproductive technology (ART).
Investors
LeadJeito Capital
Also participating
M VenturesYsios CapitalAXA IM AltsALSA Ventures
About ReproNovo
Stage
Series A
Headquarters
Lausanne, Switzerland
Founded
2021
Team Size
6–20
Sectors
healthreproductive_medicinebiotechdrug_developmentb2b